Mechanisms Underlying Radioresistance and Reversal Strategies in Non-Small Cell Lung Cancer
Open Access
- 8 July 2025
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (14) , 6559
Abstract
Radiotherapy (RT) continues to be a fundamental component in the management of non-small cell lung cancer (NSCLC). Nevertheless, some NSCLC patients do not attain optimal therapeutic outcomes due to the emergence of radioresistance. Improving the effectiveness of RT in NSCLC necessitates a thorough comprehension of the mechanisms that lead to radioresistance. This review delineates various potential mechanisms of radioresistance in NSCLC, encompassing augmented DNA damage repair, cell cycle dysregulation, cancer stem cells (CSCs), epithelial–mesenchymal transition (EMT), tumor hypoxia, an immunosuppressive tumor microenvironment (TME), dysregulation of cell death pathways, metabolic reprogramming, exosome-mediated signaling, genetic mutations, aberrant activation of signaling pathways, and epigenetic modifications. In addition, this study explores various novel strategies aimed at enhancing the radiosensitivity of NSCLC and provides a concise overview of potential biomarkers predictive of RT response, which may contribute to the development of innovative combination therapies to address radioresistance and improve patient outcomes.Keywords
Funding Information
- National Natural Science Foundation of China (82473378, LYRC202407, TJ-FK-YXJC022, 2021071, SKPY2021006)
- Shanghai Pulmonary Hospital (82473378, LYRC202407, TJ-FK-YXJC022, 2021071, SKPY2021006)
- Tongji University (82473378, LYRC202407, TJ-FK-YXJC022, 2021071, SKPY2021006)
- Shanghai Talents development fund Project (82473378, LYRC202407, TJ-FK-YXJC022, 2021071, SKPY2021006)
- Shanghai Pulmonary Hospital (82473378, LYRC202407, TJ-FK-YXJC022, 2021071, SKPY2021006)
This publication has 130 references indexed in Scilit:
- Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non–Small Cell Lung CancerJAMA Oncology, 2023
- A PI3K gene expression signature predicts for recurrence in early‐stage non–small cell lung cancer treated with stereotactic body radiation therapyCancer, 2023
- Nanoparticle‐Mediated Radiotherapy Remodels the Tumor Microenvironment to Enhance Antitumor EfficacyAdvanced Materials, 2023
- LncRNA PCAT1 activates SOX2 and suppresses radioimmune responses via regulating cGAS/STING signalling in non‐small cell lung cancerClinical and Translational Medicine, 2022
- Combined treatment of non‐small cell lung cancer using radiotherapy and immunotherapy: challenges and updatesCancer Communications, 2021
- Overcoming the senescence‐associated secretory phenotype (SASP): a complex mechanism of resistance in the treatment of cancerMolecular Oncology, 2021
- GSK-3β in DNA repair, apoptosis, and resistance of chemotherapy, radiotherapy of cancerBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2020
- Gold nanoparticles for applications in cancer radiotherapy: Mechanisms and recent advancementsAdvanced Drug Delivery Reviews, 2017
- Mitochondrial induction as a potential radio-sensitizer in lung cancer cells - a short reportCellular Oncology, 2015
- Vorinostat as a radiosensitizer for brain metastasis: a phase I clinical trialJournal of Neuro-Oncology, 2014